Evidence map›Paper›PMID 38117880›Full record

ArticleScience advances2023

Hybrid cavity-antenna architecture for strong and tunable sideband-selective molecular Raman scattering enhancement.

Ilan Shlesinger, Jente Vandersmissen, Eitan Oksenberg, Ewold Verhagen, A Femius Koenderink

Abstract read
In one paragraph

Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ilan ShlesingerDepartment of Information in Matter and Center for Nanophotonics, AMOLF, Science Park 104, 1098 XG Amsterdam, Netherlands.ORCID 0000-0002-9328-1926
Jente VandersmissenDepartment of Information in Matter and Center for Nanophotonics, AMOLF, Science Park 104, 1098 XG Amsterdam, Netherlands.
Eitan OksenbergDepartment of Information in Matter and Center for Nanophotonics, AMOLF, Science Park 104, 1098 XG Amsterdam, Netherlands.ORCID 0000-0001-9462-3986
Ewold VerhagenDepartment of Information in Matter and Center for Nanophotonics, AMOLF, Science Park 104, 1098 XG Amsterdam, Netherlands.ORCID 0000-0002-0276-8430
A Femius KoenderinkDepartment of Information in Matter and Center for Nanophotonics, AMOLF, Science Park 104, 1098 XG Amsterdam, Netherlands.ORCID 0000-0003-1617-5748

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasmon resonances at the surface of metallic antennas allow for extreme enhancement of Raman scattering. Intrinsic to plasmonics, however, is that extreme field confinement lacks precise spectral control, which would hold great promise in shaping the optomechanical interaction between light and molecular vibrations. We demonstrate an experimental platform composed of a plasmonic nanocube-on-mirror antenna coupled to an open, tunable Fabry-Perot microcavity for selective addressing of individual vibrational lines of molecules with strong Raman scattering enhancement. Multiple narrow and intense optical resonances arising from the hybridization of the cavity modes and the plasmonic broad resonance are used to simultaneously enhance the laser pump and the local density of optical states, and are characterized using rigorous modal analysis. The versatile bottom-up fabrication approach permits quantitative comparison with the bare nanocube-on-mirror system, both theoretically and experimentally. This shows that the hybrid system allows for similar SERS enhancement ratios with narrow optical modes, paving the way for dynamical backaction effects in molecular optomechanics.

Identifiers

PMID38117880
PMCPMC10732519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.